HRP20192140T1 - Režimi doziranja anti-folr1 imunokonjugata - Google Patents

Režimi doziranja anti-folr1 imunokonjugata Download PDF

Info

Publication number
HRP20192140T1
HRP20192140T1 HRP20192140TT HRP20192140T HRP20192140T1 HR P20192140 T1 HRP20192140 T1 HR P20192140T1 HR P20192140T T HRP20192140T T HR P20192140TT HR P20192140 T HRP20192140 T HR P20192140T HR P20192140 T1 HRP20192140 T1 HR P20192140T1
Authority
HR
Croatia
Prior art keywords
immunoconjugate
amino acid
acid sequence
antibody
seq
Prior art date
Application number
HRP20192140TT
Other languages
English (en)
Croatian (hr)
Inventor
Robert J. Lutz
Jose Ponte
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192140(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of HRP20192140T1 publication Critical patent/HRP20192140T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20192140TT 2013-10-08 2014-10-08 Režimi doziranja anti-folr1 imunokonjugata HRP20192140T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361888365P 2013-10-08 2013-10-08
US201361888337P 2013-10-08 2013-10-08
US201461948363P 2014-03-05 2014-03-05
US201462004815P 2014-05-29 2014-05-29
PCT/US2014/059716 WO2015054400A2 (en) 2013-10-08 2014-10-08 Anti-folr1 immunoconjugate dosing regimens
EP14852834.2A EP3055332B1 (en) 2013-10-08 2014-10-08 Anti-folr1 immunoconjugate dosing regimens

Publications (1)

Publication Number Publication Date
HRP20192140T1 true HRP20192140T1 (hr) 2020-03-06

Family

ID=52813740

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20192140TT HRP20192140T1 (hr) 2013-10-08 2014-10-08 Režimi doziranja anti-folr1 imunokonjugata
HRP20240917TT HRP20240917T1 (hr) 2013-10-08 2014-10-08 Režimi doziranja anti-folr1 imunokonjugata

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20240917TT HRP20240917T1 (hr) 2013-10-08 2014-10-08 Režimi doziranja anti-folr1 imunokonjugata

Country Status (29)

Country Link
US (3) US20150132323A1 (enExample)
EP (3) EP4424323A3 (enExample)
JP (5) JP6463744B2 (enExample)
KR (7) KR102303874B1 (enExample)
CN (1) CN106164093A (enExample)
AU (4) AU2014331964C1 (enExample)
BR (1) BR112016007479A2 (enExample)
CA (1) CA2926325C (enExample)
CY (1) CY1122449T1 (enExample)
DK (2) DK3055332T3 (enExample)
ES (2) ES2983055T3 (enExample)
FI (1) FI3653228T3 (enExample)
HR (2) HRP20192140T1 (enExample)
HU (2) HUE046696T2 (enExample)
IL (4) IL298044B2 (enExample)
LT (2) LT3653228T (enExample)
MX (2) MX384973B (enExample)
MY (1) MY174670A (enExample)
NZ (2) NZ718766A (enExample)
PL (2) PL3055332T3 (enExample)
PT (2) PT3653228T (enExample)
RS (2) RS59644B1 (enExample)
RU (1) RU2696579C2 (enExample)
SG (3) SG11201602361UA (enExample)
SI (2) SI3055332T1 (enExample)
SM (1) SMT201900694T1 (enExample)
UA (1) UA119541C2 (enExample)
WO (1) WO2015054400A2 (enExample)
ZA (1) ZA201902009B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55738B1 (sr) 2010-02-24 2017-07-31 Immunogen Inc Imunokonjugati protiv folatnog receptora 1 i njihove upotrebe
BR112013025415B1 (pt) * 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
MX362514B (es) 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
RU2015149285A (ru) * 2013-05-14 2017-06-19 Иммьюноджен Инк. Схемы дозирования иммуноконъюгата anti-folr1
PL3038650T3 (pl) 2013-08-30 2021-11-22 Immunogen, Inc. Przeciwciała i testy do wykrywania receptora folianu 1
KR102700777B1 (ko) * 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
AU2018269173A1 (en) * 2017-05-16 2019-11-28 Immunogen, Inc. Anti-FOLR1 immunoconjugates and anti-PD-1 antibody combinations
RU2020111503A (ru) * 2017-09-18 2021-10-20 Сутро Биофарма, Инк. Конъюгаты антитела к рецептору фолиевой кислоты альфа и их применение
US11873335B2 (en) 2018-03-13 2024-01-16 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
EP3821006A4 (en) * 2018-07-09 2022-12-07 Multitude Inc. FOLATE RECEPTOR ALPHA SPECIFIC ANTIBODIES
CN114222756A (zh) 2019-04-29 2022-03-22 伊缪诺金公司 双互补位FR-α抗体和免疫缀合物
CA3220817A1 (en) * 2021-06-04 2022-12-08 Eric WESTIN Treatment of cancer in patients with soluble fr-alpha
EP4440625A1 (en) * 2021-12-01 2024-10-09 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
WO2023116911A1 (zh) * 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6544787B1 (en) * 1996-11-15 2003-04-08 Hadash Medical Research Services And Development Ltd. Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
EP1133565B1 (en) 1999-07-02 2010-09-22 MorphoSys AG Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
GB0202319D0 (en) 2002-02-01 2002-03-20 Calex Electronics Ltd Apparatus
US20080131366A1 (en) * 2003-03-17 2008-06-05 Manohar Ratnam Folate Receptor Gene Modulation For Cancer Diagnosis And Therapy
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
DE602006012816D1 (de) * 2005-03-30 2010-04-22 Endocyte Inc Tifizierung von zellulären folat vitamin rezeptoren
EP1937307A4 (en) * 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
WO2009092014A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2009094456A2 (en) * 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
KR20230003298A (ko) 2008-04-30 2023-01-05 이뮤노젠 아이엔씨 가교제 및 그 용도
AU2009335943A1 (en) * 2008-12-19 2013-10-24 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
AU2010310577A1 (en) * 2009-10-21 2012-04-19 Immunogen, Inc. Novel dosing regimen and method of treatment
RS55738B1 (sr) 2010-02-24 2017-07-31 Immunogen Inc Imunokonjugati protiv folatnog receptora 1 i njihove upotrebe
US8530122B2 (en) 2010-07-30 2013-09-10 Konica Minolta Business Technologies, Inc. Foil transferring face forming toner and image forming method
ES2780192T3 (es) * 2010-11-05 2020-08-24 Eisai Inc Folato receptor alfa como marcador diagnóstico y de pronóstico para cánceres que expresan folato receptor alfa
BR112013025415B1 (pt) 2011-04-01 2021-03-16 Immunogen, Inc uso de um imunoconjugado antirreceptor de folato 1 (folr1)
WO2012138749A1 (en) * 2011-04-04 2012-10-11 Immunogen, Inc. Methods for decreasing ocular toxicity of antibody drug conjugates
MX362514B (es) * 2012-08-31 2019-01-22 Immunogen Inc Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato.
KR102279451B1 (ko) * 2013-04-08 2021-07-19 버그 엘엘씨 코엔자임 q10 병용 요법을 이용한 암 치료
RU2015149285A (ru) * 2013-05-14 2017-06-19 Иммьюноджен Инк. Схемы дозирования иммуноконъюгата anti-folr1
PL3038650T3 (pl) * 2013-08-30 2021-11-22 Immunogen, Inc. Przeciwciała i testy do wykrywania receptora folianu 1
KR102700777B1 (ko) * 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합

Also Published As

Publication number Publication date
RS59644B1 (sr) 2020-01-31
MX2016004411A (es) 2016-07-05
WO2015054400A2 (en) 2015-04-16
PL3055332T3 (pl) 2020-02-28
PL3653228T3 (pl) 2024-11-12
MY174670A (en) 2020-05-06
US20210155688A1 (en) 2021-05-27
NZ718766A (en) 2020-02-28
CA2926325C (en) 2023-08-01
EP4424323A3 (en) 2024-11-13
SI3055332T1 (sl) 2020-02-28
EP3653228B1 (en) 2024-05-15
EP3653228A1 (en) 2020-05-20
LT3653228T (lt) 2024-07-25
AU2018278880A1 (en) 2019-01-03
EP3055332A2 (en) 2016-08-17
IL244772A0 (en) 2016-04-21
JP2019218386A (ja) 2019-12-26
IL298044B1 (en) 2024-07-01
RU2016114708A (ru) 2017-11-15
KR102115217B1 (ko) 2020-05-26
IL298044A (en) 2023-01-01
ES2983055T3 (es) 2024-10-21
CN106164093A (zh) 2016-11-23
IL298044B2 (en) 2024-11-01
UA119541C2 (uk) 2019-07-10
IL313730A (en) 2024-08-01
KR20210118220A (ko) 2021-09-29
EP4424323A2 (en) 2024-09-04
DK3653228T3 (da) 2024-07-15
US20240368270A1 (en) 2024-11-07
WO2015054400A3 (en) 2015-06-25
EP3055332A4 (en) 2017-05-31
HRP20240917T1 (hr) 2024-10-11
KR20230145544A (ko) 2023-10-17
AU2014331964A1 (en) 2016-04-28
PT3055332T (pt) 2019-12-09
MX384973B (es) 2025-03-14
AU2020264270A1 (en) 2020-11-26
RU2016114708A3 (enExample) 2018-07-31
KR20210041124A (ko) 2021-04-14
HUE067367T2 (hu) 2024-10-28
JP6463744B2 (ja) 2019-02-06
KR20240027861A (ko) 2024-03-04
MX2021009222A (es) 2021-09-08
RS65798B1 (sr) 2024-08-30
JP2021178847A (ja) 2021-11-18
JP6581279B2 (ja) 2019-09-25
KR20200058592A (ko) 2020-05-27
FI3653228T3 (fi) 2024-07-04
AU2014331964B2 (en) 2018-09-13
LT3055332T (lt) 2020-04-10
KR102303874B1 (ko) 2021-09-17
CY1122449T1 (el) 2021-01-27
EP3055332B1 (en) 2019-09-25
JP7386208B2 (ja) 2023-11-24
ZA201902009B (en) 2020-10-28
HK1226671A1 (en) 2017-10-06
CA2926325A1 (en) 2015-04-16
KR20220136468A (ko) 2022-10-07
SI3653228T1 (sl) 2024-09-30
IL265586A (en) 2019-05-30
KR20160079797A (ko) 2016-07-06
KR102639861B1 (ko) 2024-02-22
DK3055332T3 (da) 2019-12-09
SG10202102555TA (en) 2021-04-29
AU2024201615A1 (en) 2024-04-04
HUE046696T2 (hu) 2020-03-30
ES2759426T3 (es) 2020-05-11
PT3653228T (pt) 2024-07-17
NZ757964A (en) 2022-07-01
SG10201907042PA (en) 2019-09-27
SG11201602361UA (en) 2016-04-28
AU2020264270B2 (en) 2024-01-18
JP2024016239A (ja) 2024-02-06
JP2019031568A (ja) 2019-02-28
IL244772B (en) 2019-05-30
BR112016007479A2 (pt) 2017-09-12
SMT201900694T1 (it) 2020-01-14
AU2014331964C1 (en) 2019-10-31
JP2016534039A (ja) 2016-11-04
US20150132323A1 (en) 2015-05-14
KR102115217B9 (ko) 2021-12-24
RU2696579C2 (ru) 2019-08-05

Similar Documents

Publication Publication Date Title
HRP20192140T1 (hr) Režimi doziranja anti-folr1 imunokonjugata
TWI780083B (zh) 抗pd-1抗體及組成物
AU2019201513B2 (en) Therapy involving antibodies against Claudin 18.2 for treatment of cancer
TWI859319B (zh) 抗ｃｄ７３抗體及組合物
RU2018111205A (ru) Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
JP2019031568A5 (enExample)
JP2025129187A5 (enExample)
JP2016520082A5 (enExample)
JP2018527383A5 (enExample)
WO2019084553A1 (en) ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
HRP20211125T1 (hr) Konjugati protutijelo-lijek koji se temelje na eribulinu i postupci uporabe
JP2017535257A5 (enExample)
CN114599681B (zh) 新型抗cd47抗体及其用途
HRP20202047T1 (hr) Antitijelo za igf-1r i njegova upotreba kao usmjeravajućeg vezikula za liječenje karcinoma
JP2017535246A5 (enExample)
RU2016124540A (ru) Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
RU2019141270A (ru) Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител
JP2020519675A5 (enExample)
AU2018291081A1 (en) Use of anti-FAM19A5 antibodies for treating cancers
BR112020016986A2 (pt) formulações de anticorpo contra b7-h4
EP3625260A1 (en) Treatment of cancer with anti-gitr agonist antibodies
CN107531773A (zh) 用于增强癌症治疗的效果的组合物和方法
JP2016534039A5 (enExample)
JP2016525560A5 (enExample)